home / stock / phio / phio quote
Last: | $0.65 |
---|---|
Change Percent: | 1.91% |
Open: | $0.639 |
Close: | $0.6378 |
High: | $0.65 |
Low: | $0.612 |
Volume: | 23,223 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.65 | $0.639 | $0.6378 | $0.65 | $0.612 | 23,223 | 04-19-2024 |
$0.6378 | $0.6283 | $0.6378 | $0.638 | $0.604849 | 61,688 | 04-18-2024 |
$0.649 | $0.65 | $0.649 | $0.650001 | $0.625 | 41,365 | 04-17-2024 |
$0.6542 | $0.649 | $0.6542 | $0.66 | $0.6405 | 20,631 | 04-16-2024 |
$0.6656 | $0.67 | $0.6656 | $0.68 | $0.649 | 49,481 | 04-15-2024 |
$0.6739 | $0.698 | $0.6739 | $0.698 | $0.6612 | 52,536 | 04-12-2024 |
$0.6995 | $0.7079 | $0.6995 | $0.716027 | $0.662 | 54,913 | 04-11-2024 |
$0.682 | $0.7 | $0.682 | $0.7 | $0.65 | 24,599 | 04-10-2024 |
$0.68 | $0.69 | $0.68 | $0.7 | $0.66 | 49,075 | 04-09-2024 |
$0.6901 | $0.6908 | $0.6901 | $0.699 | $0.67 | 46,536 | 04-08-2024 |
$0.689 | $0.709 | $0.689 | $0.718 | $0.675 | 96,948 | 04-05-2024 |
$0.6932 | $0.719 | $0.6932 | $0.719 | $0.6704 | 94,790 | 04-04-2024 |
$0.6999 | $0.68 | $0.6999 | $0.7198 | $0.65 | 72,883 | 04-03-2024 |
$0.67 | $0.65 | $0.67 | $0.699899 | $0.63 | 122,415 | 04-02-2024 |
$0.666 | $0.6804 | $0.666 | $0.7239 | $0.66 | 64,359 | 04-01-2024 |
$0.68 | $0.73 | $0.68 | $0.73 | $0.66 | 128,814 | 03-29-2024 |
$0.68 | $0.73 | $0.68 | $0.73 | $0.66 | 128,814 | 03-28-2024 |
$0.7261 | $0.76 | $0.7261 | $0.76 | $0.71 | 54,142 | 03-27-2024 |
$0.73 | $0.76 | $0.73 | $0.77 | $0.73 | 56,809 | 03-26-2024 |
$0.76 | $0.74 | $0.76 | $0.76 | $0.7136 | 92,008 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose pr...
MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is ...
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose pr...